UK stocks experienced a recovery alongside European markets following a downturn driven by tariffs. The FTSE 100 index increased by 0.7%, rebounding from a 0.9% decline recorded the day before. AstraZeneca's shares saw a rise of up to 2% after a mid-stage trial revealed that its experimental drug for cholesterol significantly lowered levels of "bad" cholesterol. In contrast, shares of Travis Perkins tumbled by 13%, reaching their lowest point since 2009, due to disappointing results and a cautious future outlook, hinting at possible downgrades in analysts' projections. Additionally, UK house prices in March did not change, falling short of the anticipated 0.2% growth, although the yearly price growth remained stable at 3.9%, based on data from Nationwide.